442 related articles for article (PubMed ID: 26327494)
1. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression.
Zhu J; Chin K; Aerbajinai W; Kumkhaek C; Li H; Rodgers GP
Blood; 2014 Aug; 124(7):1146-56. PubMed ID: 24914133
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
Walker AL; Steward S; Howard TA; Mortier N; Smeltzer M; Wang YD; Ware RE
Blood; 2011 Nov; 118(20):5664-70. PubMed ID: 21921042
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNA in hydroxyurea mediated HbF induction in sickle cell anaemia patients.
Kargutkar N; Sawant-Mulay M; Hariharan P; Chandrakala S; Nadkarni A
Sci Rep; 2023 Jan; 13(1):369. PubMed ID: 36611033
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.
Nahavandi M; Tavakkoli F; Wyche MQ; Perlin E; Winter WP; Castro O
Br J Haematol; 2002 Dec; 119(3):855-7. PubMed ID: 12437671
[TBL] [Abstract][Full Text] [Related]
6. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
[TBL] [Abstract][Full Text] [Related]
7. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
8. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
9. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
10. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
11. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.
Lettre G; Sankaran VG; Bezerra MA; Araújo AS; Uda M; Sanna S; Cao A; Schlessinger D; Costa FF; Hirschhorn JN; Orkin SH
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11869-74. PubMed ID: 18667698
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X; Hu T; Ho MH; Wang Y; Yu M; Patel N; Pi W; Choi JH; Xu H; Ganapathy V; Kutlar F; Kutlar A; Tuan D
Haematologica; 2017 Dec; 102(12):1995-2004. PubMed ID: 28971909
[TBL] [Abstract][Full Text] [Related]
13. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
14. The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.
Ikuta T; Adekile AD; Gutsaeva DR; Parkerson JB; Yerigenahally SD; Clair B; Kutlar A; Odo N; Head CA
Blood Cells Mol Dis; 2011 Dec; 47(4):235-42. PubMed ID: 21945571
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wonkam A
Clin Transl Med; 2016 Mar; 5(1):15. PubMed ID: 27056246
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK
Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
18. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
19. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
20. Association between BCL11A, HSB1L-MYB, and XmnI γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patients.
El-Ghamrawy M; Yassa ME; Tousson AMS; El-Hady MA; Mikhaeil E; Mohamed NB; Khorshied MM
Ann Hematol; 2020 Oct; 99(10):2279-2288. PubMed ID: 32772141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
